JAM2
Junctional adhesion molecule B
Also known as: C21orf43, CD322, JAM-2, JAM-B, JAM2_HUMAN, JAMB, VE-JAM
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P57087
- Gene
- JAM2
- Ensembl
- ENSG00000154721
- Chromosome
- 21
- Canonical length
- 298 aa
- Protein class
- CD markers, Disease related genes, Human disease related genes, Predicted membrane proteins
- Subcellular location
- Nucleoplasm,Plasma membrane
OverviewNCBI Gene
This gene belongs to the immunoglobulin superfamily, and the junctional adhesion molecule (JAM) family. The protein encoded by this gene is a type I membrane protein that is localized at the tight junctions of both epithelial and endothelial cells. It acts as an adhesive ligand for interacting with a variety of immune cell types, and may play a role in lymphocyte homing to secondary lymphoid organs. Alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Jul 2012]
Canonical amino-acid sequenceUniProt
298 residues, UniProt reviewed canonical sequence.
>P57087|JAM2
1 MARRSRHRLL LLLLRYLVVA LGYHKAYGFS APKDQQVVTA VEYQEAILAC KTPKKTVSSR
61 LEWKKLGRSV SFVYYQQTLQ GDFKNRAEMI DFNIRIKNVT RSDAGKYRCE VSAPSEQGQN
121 LEEDTVTLEV LVAPAVPSCE VPSSALSGTV VELRCQDKEG NPAPEYTWFK DGIRLLENPR
181 LGSQSTNSSY TMNTKTGTLQ FNTVSKLDTG EYSCEARNSV GYRRCPGKRM QVDDLNISGI
241 IAAVVVVALV ISVCGLGVCY AQRKGYFSKE TSFQKSNSSS KATTMSENDF KHTKSFIILocalizationUniProt · AlphaFold · HPA
Whether an antibody against JAM2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.4
- Highest tissue expression
- 60 nTPM
Expression across tissuesHPA
Tissue
- placenta: 60 nTPM
- basal ganglia: 21 nTPM
- midbrain: 20 nTPM
- adipose tissue: 19 nTPM
- ovary: 19 nTPM
- cerebral cortex: 19 nTPM
Single-cell type
- sertoli cells: 322 nCPM
- vascular endothelial cells: 269 nCPM
- bergmann glia: 151 nCPM
- astrocytes: 115 nCPM
- pituicytes/fscs: 108 nCPM
- microglia: 101 nCPM
Immune cell
- naive B-cell: 0.6 nTPM
- NK-cell: 0.6 nTPM
- basophil: 0.4 nTPM
- plasmacytoid DC: 0.4 nTPM
- neutrophil: 0.3 nTPM
- memory CD8 T-cell: 0.2 nTPM
Brain region
- spinal cord: 50 nTPM
- medulla oblongata: 48 nTPM
- thalamus: 47 nTPM
- cerebellum: 43 nTPM
- midbrain: 41 nTPM
- white matter: 40 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about JAM2.
Disease | AllUniProt
Conditions JAM2 is implicated in, by any mechanism.
- Basal ganglia calcification, idiopathic, 8, autosomal recessive (IBGC8) MIM:618824
Disease | GeneticClinVar
8 pathogenic / likely-pathogenic of 89 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Basal ganglia calcification, idiopathic, 8, autosomal recessive
- JAM2-related disorder
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.7
- gnomAD pLI
- 0.01
- gnomAD missense Z
- 1.08
- DepMap mean gene effect
- -0.02
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cell-cell adhesion
- cellular extravasation
- hematopoietic stem cell migration to bone marrow
- leukocyte cell-cell adhesion
- leukocyte tethering or rolling
- lymphocyte aggregation
- maintenance of blood-brain barrier
- negative regulation of myelination
- positive regulation of lymphocyte migration
- spermatid development
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of JAM2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads JAM2 as an antibody target. Whether an autoantibody or antibody against JAM2 could matter depends on whether native JAM2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
JAM2 is annotated at the cell surface, where native JAM2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label JAM2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...